Cross-species genomic and functional analyses identify a combination therapy using a CHK1 inhibitor and a ribonucleotide reductase inhibitor to treat triple-negative breast cancer.
about
Trial Watch: Targeting ATM-CHK2 and ATR-CHK1 pathways for anticancer therapyRoles of Chk1 in cell biology and cancer therapyTranscriptomic classification of genetically engineered mouse models of breast cancer identifies human subtype counterparts.Luminal progenitor and fetal mammary stem cell expression features predict breast tumor response to neoadjuvant chemotherapy.Genomic profiling of murine mammary tumors identifies potential personalized drug targets for p53-deficient mammary cancers.Aberrant DNA Double-strand Break Repair Threads in Breast Carcinoma: Orchestrating Genomic Insult Survival.Targeting ribonucleotide reductase for cancer therapy.Personalised Medicine: Genome Maintenance Lessons Learned from Studies in Yeast as a Model Organism.Differential response of normal and malignant urothelial cells to CHK1 and ATM inhibitors.Targeted inhibition of ATR or CHEK1 reverses radioresistance in oral squamous cell carcinoma cells with distal chromosome arm 11q loss.Regulation of epithelial-mesenchymal transition in breast cancer cells by cell contact and adhesion.Schedule dependent synergy of gemcitabine and doxorubicin: Improvement of in vitro efficacy and lack of in vitro-in vivo correlation.Association of novel gene polymorphisms RRM1 -756T>C and -269 C>A with breast cancer.Somatic loss of WWOX is associated with TP53 perturbation in basal-like breast cancer
P2860
Q26745686-9BB5353A-73A8-49A1-A948-E0705D787D73Q28289548-098172CE-906C-475F-9215-9C031C6F1C94Q33742688-83F4A5F8-0C87-4CE5-8F70-7C641E684232Q35020412-5AD68C2B-A446-4157-9008-BD59E4762760Q37120418-3171C4B1-C67C-459D-84A9-B19899FCE4A5Q37552296-B59FA807-29E5-4E81-B29F-8F0E827DE39CQ38148222-58F1DF14-02D5-43F8-9D9E-0182B1433E85Q38608688-53B6FE6D-4368-4B92-94AE-A06A48BA2CAEQ38973685-3423B847-71EA-48B2-92D8-8ECC22CEE7A3Q39044559-0C930D56-104D-4D52-B563-97D1FC8A54E7Q43144068-0EC90FE3-3E2A-4FC5-9202-4C51C9571387Q53465288-CF288D0A-550B-41EC-81A0-F9C6736440D8Q54220808-7CD1D117-6473-4D1D-B0D8-AEF29882C56FQ58799648-4BF04EF2-9FD5-4769-AC4B-0C152A3A8F21
P2860
Cross-species genomic and functional analyses identify a combination therapy using a CHK1 inhibitor and a ribonucleotide reductase inhibitor to treat triple-negative breast cancer.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Cross-species genomic and func ...... triple-negative breast cancer.
@en
type
label
Cross-species genomic and func ...... triple-negative breast cancer.
@en
prefLabel
Cross-species genomic and func ...... triple-negative breast cancer.
@en
P2093
P2860
P356
P1476
Cross-species genomic and func ...... triple-negative breast cancer
@en
P2093
Aleksandra M Michalowski
Christina N Bennett
Christine C Tomlinson
Dror Luger
Helen Piwinica-Worms
Isabel M Chu
James Shou
Jeffrey E Green
Lara R Mittereder
Melinda G Hollingshead
P2860
P2888
P356
10.1186/BCR3230
P577
2012-07-19T00:00:00Z
P5875
P6179
1041110568